… , suggesting that EML4-ALK has an oncogenic effect. … In the EML4-ALK fusion gene, the
EML4 gene fragments all … as the EGFR inhibitor erlotinib, cyclin-dependent kinase inhibitor, and …

… of the ALK gene occurs at exon 20, whereas the EML4 breakpoint differs to generate fusion
protein variants.5, 6, 7 More than 15 EML4-ALK fusion … of particular EML4-ALK variants may …

… The efficacy of crizotinib treatment for recurring EML4-ALK-positive non-small cell lung cancer
(NSCLC… Crizotinib, the first ALK-tyrosine kinase inhibitor (TKI), has been associated with a …

… EML4-ALK is an oncogenic fusion protein that accounts for … a much lower sensitivity to the
ALK tyrosine kinase inhibitor (TKI), … generation of more efficacious ALK inhibitors, most patients …

… Lorlatinib, a third-generation ALK tyrosine kinase inhibitor, … with previously untreated
ALK-positive advanced NSCLC in the … -generation ALK inhibitors in ALK-rearranged lung cancer …

… efficacy and safety data and impact of the EML4-ALK fusion variant on the efficacy of Alectinib
in untreated ALK… by NGS showed that the two ALK fusion genes disappeared. As of April …

… and duration to ALK-tyrosine kinase inhibitors (ALK-TKIs). With the … the effect of EML4-ALK
subtypes on the prognosis of early lung … EML4-ALK fusion gene in non-small-cell lung cancer …

… , for example G1202R, reducing inhibitor effectiveness. Here, … Anaplastic lymphoma
kinase-tyrosine kinase inhibitors … type of the EML4-ALK fusion protein confers differential response …

… Although multiple ALK tyrosine kinase inhibitors (ALK-TKIs) have been … -positive patients
with non-small cell lung cancer. … between EML4-ALK fusion variants and clinical efficacy in ALK-…

… ALK fusions and ALK with or without TP53 mutations were assessed by next-generation …
review based on EML4::ALK variants and ALK with or without TP53 or other mutation status. …